11.03.2021 06:59:47
|
Press Release: Addex Reports Full Year 2020 -2-
Telephone: +41 22 884 15 +44 (0)20 7318 2955 (646)-755-7412
55 mailto:msinclair@halsin.com james@haydenir.com
mailto:PR@addextherapeutics.com msinclair@halsin.com
PR@addextherapeutics.com
-------------------------------- ----------------------------
Forward Looking Statements:
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended, including in respect of the anticipated initiation of clinical
trials. The words "may," "will," "could," "would," "should," "expect,"
"plan," "anticipate," "intend," "believe," "estimate," "predict,"
"project," "potential," "continue," "target" and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release, are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed or
implied by any forward-looking statements contained in this press
release, including, without limitation, uncertainties related to market
conditions. These and other risks and uncertainties are described in
greater detail in the section entitled "Risk Factors" in Addex
Therapeutics' Annual Report on Form 20-F for the year ended December 31,
2019, as filed with the SEC on April 27, 2020, the prospectus related to
the global offering and other filings that Addex Therapeutics may make
with the SEC in the future. Any forward-looking statements contained in
this press release represent Addex Therapeutics' views only as of the
date hereof and should not be relied upon as representing its views as
of any subsequent date. Addex Therapeutics explicitly disclaims any
obligation to update any forward-looking statements.
(END) Dow Jones Newswires
March 11, 2021 01:00 ET (06:00 GMT)

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Addex Therapeutics Ltd.mehr Nachrichten
21.02.25 |
Handel in Zürich: SPI schlussendlich mit positivem Vorzeichen (finanzen.at) | |
19.02.25 |
SPI-Papier Addex Therapeutics-Aktie: So viel hätten Anleger mit einem Investment in Addex Therapeutics von vor einem Jahr verloren (finanzen.at) | |
18.02.25 |
Handel in Zürich: Das macht der SPI am Dienstagnachmittag (finanzen.at) | |
18.02.25 |
Anleger in Zürich halten sich zurück: SPI schwächer (finanzen.at) | |
17.02.25 |
Zuversicht in Zürich: nachmittags Pluszeichen im SPI (finanzen.at) | |
17.02.25 |
SIX-Handel: SPI am Mittag mit positivem Vorzeichen (finanzen.at) | |
17.02.25 |
Freundlicher Handel in Zürich: SPI zeigt sich zum Start des Montagshandels fester (finanzen.at) | |
13.02.25 |
SPI aktuell: SPI schlussendlich mit Gewinnen (finanzen.at) |
Analysen zu Addex Therapeutics Ltd.mehr Analysen
Aktien in diesem Artikel
Addex Therapeutics Ltd. | 1,37 | -17,96% |
|